Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 11/20 | 0.79 |
| ▸ | PDGFRA | P16234 | 11/20 | 0.79 |
| ▸ | HPGDS | O60760 | 3/20 | 0.58 |
| ▸ | EGFR | P00533 | 1/20 | 0.56 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.54 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | CASP3 | P42574 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.53 |
| ▸ | GAK | O14976 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31060559 | 0.89 | PDGFRB (1.00) | PDGFRBPDGFRAHPGDSEGFRCYP11B1 | |
| SCHEMBL9938934 | 0.85 | PDGFRB (0.70) | PDGFRBPDGFRAHPGDSCYP11B1CYP11B2 | |
| SCHEMBL3010687 | 0.85 | PDGFRB (0.74) | PDGFRBPDGFRAHPGDSEGFRCYP11B1 | |
| SCHEMBL3012534 | 0.85 | PDGFRB (0.65) | PDGFRBPDGFRACYP11B1CYP11B2NPC1 | |
| SCHEMBL9938178 | 0.84 | PDGFRB (0.63) | PDGFRBPDGFRAHPGDSCYP11B1CYP11B2 | |
| SCHEMBL8501467 | 0.83 | PDGFRB (1.00) | PDGFRBPDGFRAEGFR | |
| SCHEMBL28808959 | 0.82 | HPGDS (0.65) | PDGFRBPDGFRAHPGDSEGFRCYP11B1 | |
| SCHEMBL8500071 | 0.82 | PDGFRB (1.00) | PDGFRBPDGFRAHPGDSEGFRNPC1 | |
| SCHEMBL31060313 | 0.82 | PDGFRB (1.00) | PDGFRBPDGFRAHPGDSEGFRNPC1 | |
| SCHEMBL18318771 | 0.80 | PDGFRB (0.57) | PDGFRBPDGFRAHPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150057218-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS INC (US) | 2015-02-26 | — | — | US | disclosed |
| US-20150057218-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS INC (US) | 2015-02-26 | — | — | US | disclosed |
| US-8921369-B2 | Inhibitors of HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-8921369-B2 | Inhibitors of HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-8877707-B2 | Inhibitors of HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| EP-2682393-A1 | Inhibitors of HCV NS5A comprising a bicyclic core. | Presidio Pharmaceuticals, Inc. (US) | 2014-01-08 | — | — | EP | disclosed |
| US-8546392-B2 | 17Beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-related diseases | UNIVERSITAET DES SAARLANDES (DE) | 2013-10-01 | — | — | US | disclosed |
| US-8546392-B2 | 17Beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-related diseases | UNIVERSITAET DES SAARLANDES (DE) | 2013-10-01 | — | — | US | disclosed |
| US-8546392-B2 | 17Beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-related diseases | UNIVERSITAET DES SAARLANDES (DE) | 2013-10-01 | — | — | US | disclosed |
| US-20130203656-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20120122864-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122864-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| WO-2011149856-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| US-20100204234-A1 | 17Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitors for the Treatment of Hormone-Related Diseases | UNIVERSITAET DES SAARLANDES (DE) | 2010-08-12 | — | — | US | disclosed |
| US-20100204234-A1 | 17Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitors for the Treatment of Hormone-Related Diseases | UNIVERSITAET DES SAARLANDES (DE) | 2010-08-12 | — | — | US | disclosed |
| US-20100204234-A1 | 17Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitors for the Treatment of Hormone-Related Diseases | UNIVERSITAET DES SAARLANDES (DE) | 2010-08-12 | — | — | US | disclosed |
| WO-2010065674-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| EP-2131826-A2 | 17BETA-HYDROXYSTEROID-DEHYDROGENASE TYPE 1 INHIBITORS FOR THE TREATMENT OF HORMONE-DEPENDENT DISEASES | Universität des Saarlandes (DE) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008116920-A2 | 17BETA-HYDROXYSTEROID-DEHYDROGENASE TYPE 1 INHIBITORS FOR THE TREATMENT OF HORMONE-DEPENDENT DISEASES | Universität des Saarlandes (DE) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008116920-A2 | 17BETA-HYDROXYSTEROID-DEHYDROGENASE TYPE 1 INHIBITORS FOR THE TREATMENT OF HORMONE-DEPENDENT DISEASES | Universität des Saarlandes (DE) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204234-A1 | 17Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitors for the Treatment of Hormone-Related Diseases | HSD17B1, HSD17B11, HSD17B2 | PDGFRB 3789/4885PDGFRA 3911/4885HPGDS 211/4885 |
| US-20120122864-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | PDGFRB 338/4885PDGFRA 677/4885HPGDS 2085/4885 |
| US-20150057218-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | PDGFRB 338/4885PDGFRA 677/4885HPGDS 2085/4885 |
| US-20130203656-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | PDGFRB 338/4885PDGFRA 677/4885HPGDS 2085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.